Antithrombin Market Size, Share, Industry, Forecast and outlook (2024-2031)

Antithrombin Market is segmented By Usage (Therapeutics, Diagnostics, Research, Other), By Type (Anticoagulant, Antiplatelet, Thrombolytic Drug), By Route of Administration (Oral, Parenteral), By Source (Human, Recombinant Goat milk, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Antithrombin Market Size

The Global Antithrombin Market reached USD 545 million in 2022 and is projected to witness lucrative growth by reaching up to USD 775.7  million by 2030. The Global Antithrombin Market is expected to exhibit a CAGR of 4.6% during the forecast period 2023-2030. The increasing incidence of thrombotic disorders, increasing use of antithrombin in the treatment of COVID-19 patients, development of new antithrombin products, expansion of product portfolio by key players are the recent Global Antithrombin Market trends.

For instance, increasing use of antithrombin in the treatment of COVID-19 patients is found to be very beneficial, as according to the American Society of Hematology guidelines recommend that patients with COVID-19 and an existing indication for therapeutic anticoagulation or antiplatelet therapy should receive antithrombotic therapy as indicated.

Antithrombin is a glycoprotein that is synthesized by the liver and acts as a natural anticoagulant. It inhibits the activity of several proteases, including thrombin, factor Xa, and factor XIIa. Antithrombin deficiency can lead to a variety of thrombotic disorders, including deep vein thrombosis, pulmonary embolism, and stroke.

Furthermore, increasing prevalence of cardiovascular diseases, growing geriatric population, increasing awareness of the benefits of antithrombin , launch of new antithrombin products, and government initiatives are the factors expected to drive the global antithrombin market over the forecast period.

For instance, according to American Heart Association’s Heart Disease and Stroke Statistics report of 2023, 928,741 deaths were seen in U.S. in the year 2020 for the cardiovascular disease, in which coronary heart disease (CHD) holds the 41.2% of deaths, followed by strokes. Therefore owing to this reasons the growing prevalence of cardiovascular disease will drive the Global Antithrombin Market over the forecast period.

Antithrombin Market Scope

To know more insights Download Sample

Antithrombin Market Dynamics

The Growing Geriatric Population will Drive the Global Antithrombin Market Growth.

The world population is ageing, which is increasing the number of persons suffering from age-related cardiovascular illnesses. Antithrombin is an effective therapy for many disorders, and the ageing population is projected to raise global antithrombin market demand in the future years.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. In 2050, the number of persons aged 60 and up will more than treble, approaching 2.1 billion. Hence, owing to the above factors, the market is expected to drive over the forecast period.

The Side Effects Associated with the Antithrombin products are Hampering the Growth of the Global Antithrombin market.

Antithrombin products are used to treat a variety of illnesses, including inherited antithrombin deficiency, recurrent venous thromboembolism, and liver disease. Nonetheless, using these products may result in side effects such as allergic reactions, haemorrhage, and other serious complications. These negative effects may dissuade patients from using antithrombin medications, limiting the global antithrombin market's growth. Thus, owing to the above factors, the global antithrombin market is expected to hamper over the forecast period.

Antithrombin Market Segment Analysis

The Global Antithrombin Market is segmented based on usage, route of administration, type, source, and region.

The Therapeutics Segment is Expected to Hold a Dominant Position in the Global Antithrombin Market Over the Forecast Period.

Therapeutics segment is projected to dominate the global antithrombin market accounting market share of about 52.3%, owing to the rising occurrence of disorders linked with antithrombin deficiency, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC) and also due to sepsis inflammation. In addition, the rising awareness about the benefits of antithrombin therapy is also expected to drive the growth of this segment. 

Moreover the devlopment in new antithrombin therapies and commercialization by market player through collaboration and partnerships will help to drive the antithrombin market share for therapeutic segment. For instance, in February 2022, Grifols, a leading producer of plasma-based pharmaceuticals, partnered with Endpoint Health, a precision medicine business, focusing on solving critical care requirements connected to the immune system. 

This collaboration intends to develop and commercialize an antithrombin III (AT-III) medication for sepsis. Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Antithrombin Market Geographical Share

North America holds a dominant position in the global antithrombin market.

North America is estimated to hold around 38.8% of the total market share throughout the forecast period. Owing to the rising prevalence of cardiovascular diseases, such as heart attack, stroke, and deep vein thrombosis (DVT), which are major risk factors for blood clots, also the increasing awareness about the benefits of antithrombin therapy and the rising number of patients undergoing surgery are some of the key are the factors expected to drive the antithrombin market in North America region over the forecast period.

According to a Centres for Disease Control and Prevention (CDC) report from 2023, coronary artery disease (CAD), the most common type of heart disease that causes plaque to build up in arteries and blood clots, killed nearly 375,476 people in 2021 and affects one in every 20 adults over the age of 20, is the leading cause of death in North America. Antithrombin is a protein that prevents blood clots.Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Antithrombin Market Companies

The major global players in the market include CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., BDI Pharma, among others.

COVID-19 Impact on Antithrombin Market 

The COVID-19 pandemic has had significant effects on the Global Antithrombin Market. Antithrombin demand has decreased due to a decline in surgical operations and diagnosis of illnesses such as venous thromboembolism (VTE). The market is expected to grow in the future despite these obstacles. 

Several reasons, such as the rising incidence of cardiovascular disorders, more knowledge of the benefits of antithrombin therapy, and improvements in the creation of novel antithrombin medicines will influence this expansion.

Russia Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine has hurt the global antithrombin market, which has reduced its supply. Sanctions on Russia, supply chain hiccups, and decreased output are just a few of the causes contributing to this fall. Antithrombin costs have increased due to the reduced availability, making it more difficult for patients to purchase the medication. 

Due to a number of circumstances, the conflict has also led to a decline in the demand for antithrombin. There is less access to healthcare services, less money to spend, and more fear and worry among those who are impacted by the violence. The Russia-Ukraine conflict is anticipated to have a short-term detrimental effect on the world antithrombin market. 

On the other hand, the market is anticipated to expand over time. 

The prevalence of cardiovascular disorders is rising, antithrombin therapy is becoming more well-known, and new antithrombin products are being developed, contributing to this expansion.

By Usage

• Therapeutics
• Diagnostics
• Research
• Others

By Type

• Anticoagulant
• Antiplatelet
• Thrombolytic Drug

By Route of Administration

• Oral
• Parenteral

By Source

• Human
• Recombinant Goat Milk
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In July 2022, Fitusiran prophylaxis showed a significant decrease in bleeding episodes compared to previous prophylactic therapies using factor or bypassing agents in people with hemophilia A or B, independent of the presence of inhibitors. The number of bleeds decreased by 61% as a result of using fitusiran..
• In February 2022, Novo Holdings A/S, an eminent investor in the life sciences industry, recently announced its participation in Hemab Therapeutics' Series B Financing round, which garnered $135 million. Hemab Therapeutics is a clinical-stage biotechnology business focused on discovering novel preventative medicines for bleeding and thrombotic diseases that presently lack appropriate treatment alternatives. They aim to meet the requirements of people suffering from significant and underserved bleeding and clotting problems.

Why Purchase the Report?

• To visualize the Global Antithrombin Market segmentation based on the usage, type, route of administration, source, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of antithrombin market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Antithrombin Market Report Would Provide Approximately 49 Tables, 53 Figures And 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies